ICH Q1 — Stability Testing

The one idea

A shelf life is a hypothesis: this product, in this package, stored this way, still meets its specification for N months. Stability testing is the experiment that tests that hypothesis over real time. ICH Q1 is the agreed protocol for running that experiment so that the result means the same thing to every regulator.

This is Lecture 1’s definition of science made concrete — you state a claim, you expose it to testing, and you are obligated to revise the shelf life (or the storage statement, or the formulation) when the data say so.

The Q1 family

ICH Q1 is not one document. It is a set:

What the study is trying to establish

• Retest period (drug substance) or shelf life / expiration date (drug product).
• The storage statement that goes on the label (“Store below 25 °C”, “Do not refrigerate”, etc.).
• The degradation pathways — what breaks down, into what, and how fast.

Stress testing (forced degradation) — where the analyst cares most

Before the formal study, the drug substance is deliberately degraded: heat (typically in ~10 °C increments above accelerated — 50 °C, 60 °C…), high humidity (75 % RH or greater), acid and base hydrolysis across a pH range, oxidation, and photolysis.

The point is not the formal shelf life. The point is to:

1. Identify the likely degradation products so the method is designed to see them.
2. Demonstrate the analytical procedure is stability-indicating — it resolves the API from its degradants and can quantify them (ICH Q2 validation depends on this).
3. Check mass balance — does the loss of assay account for the rise in degradation products? A gap means a degradant you are not detecting.

If you take one thing from Q1 into the lab: forced degradation is how you prove your method can be trusted to watch a product age.

The formal study design

Batches. At least three primary batches, same synthetic route / manufacturing process, at least pilot scale, in the container closure system proposed for marketing.

Storage conditions (general case):

If 30 °C / 65 % RH is chosen as the long-term condition, there is no separate intermediate condition.

Products in semi-permeable containers (e.g. LDPE bags, plastic ampoules) are also tested for water loss at low humidity (40 °C / not more than 25 % RH).

Testing frequency. Long-term: 0, 3, 6, 9, 12, 18, 24 months, then annually through the proposed shelf life. Accelerated: 0, 3, 6 (minimum three points). Intermediate: 0, 6, 9, 12 (minimum four points).

“Significant change”

At the accelerated condition, significant change triggers intermediate testing, and the shelf life is then based on long-term data. For a drug product, significant change is any of:

• a 5 % change in assay from the initial value (or failure to meet the potency criterion for a biological/immunological method);
• any degradation product exceeding its acceptance criterion;
• failure to meet acceptance criteria for appearance, physical attributes, or functionality (some physical changes are expected under accelerated stress — e.g. softening of a suppository — and are judged in context);
• failure to meet the pH criterion;
• failure of dissolution for 12 units.

For a drug substance, significant change is simply failure to meet specification.

Climatic zones and why Q1F was withdrawn

ICH covers Zones I and II. Q1F was withdrawn in 2006 because the ICH regions do not include Zone III/IV countries; WHO and national authorities now set those requirements (WHO recommends 30 °C / 75 % RH long-term for Zone IVb).

Q1B — photostability (in brief)

Test sequence: fully exposed product → immediate pack → marketing pack, stopping once you have enough information. Minimum exposure: 1.2 million lux·hours (visible) and 200 W·h/m² (near-UV). Two lighting options — a D65/ID65 daylight standard (Option 1) or cool-white fluorescent plus a near-UV lamp (Option 2). Light dose is confirmed with a validated actinometer (e.g. quinine).

Q1D — bracketing and matrixing (reduced designs)

• Bracketing — test only the extremes of a design factor (strength, container size, fill) at every time point, on the assumption that the extremes bound the intermediates.
• Matrixing — test a subset of samples at each time point, a different subset at the next, so the full matrix is covered across the study but not at every pull.
• The trade-off — less data means less power to extrapolate. If the data turn out variable, a reduced design may not support the shelf life you wanted, and there is no going back in time.

Q1E — evaluating the data

• If accelerated data show significant change, base the shelf life on long-term (and intermediate) data.
• Extrapolation — with long-term and accelerated data showing little change and little variability, you may propose a shelf life up to 2× the long-term data period, but not more than 12 months beyond it.
• Statistics — regression analysis of each attribute against time; test whether batches can be pooled using analysis of covariance at a 0.25 significance level; the shelf life is the earliest time the 95 % one-sided confidence limit for the mean crosses an acceptance criterion.

Modernization — the revised Q1

ICH is consolidating Q1A–Q1F and Q5C (stability of biologics) into a single modernized Q1 guideline. The concept paper was endorsed in 2022 and the draft reached public consultation in 2025. The themes: explicit science- and risk-based study design, formal stability modeling (including to justify extrapolation), and clearer rules for reduced designs. Worth watching — it will change how these studies are designed within the class’s professional lifetime.

(Instructor: confirm the current Step / publication status before lecture — this is moving.)

Where the analyst sits

Every number in a stability report came from a method an analyst developed, validated as stability-indicating, and ran at each time point — sometimes for years. The judgment calls are analytical: is that a real new peak or a column artifact? Does mass balance close? Is the trend real or within method variability? Q1 is the framework; the analyst is the instrument that makes it mean something.

For discussion

• Why is forced degradation done on the drug substance before the formal study, not after?
• A product passes accelerated but a new degradant appears at 9 months long-term. What happens to the shelf life, and what does the analyst have to do first?
• When would you not use a matrixing design, even though it would save the lab months of work?

• ←Regulations & Compendia
• Q2 · Validation→